Does ticagrelor modulate the inflammatory respons to human endotoxemia? - TICA-LPS trial

niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 40 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•- History, signs or symptoms of cardiovascular disease
•- History of chronic obstructive pulmonary disease (COPD) or asthma
•- History of hemorrhagic diathesis, or any other disorder associated with increased risk of bleeding
•- Previous spontaneous vagal collapse
•- Use of any medication
•- Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrioventricular block, third degree atrioventricular block or a complex bundle branch block
•- Hypertension (defined as RR systolic > 160 mmHg or RR diastolic > 90 mmHg)
•- Hypotension (defined as RR systolic < 100 or RR diastolic < 50)
•- Renal impairment (defined as MDRD < 60 ml/min)
•- Liver enzyme abnormalities ((defined as ALAT and/or ASAT > twice upper limit of normality)
•- Thrombocytopenia (<150*109/ml) or anemia (haemoglobin < 8.0 mmol/L)
•- Any obvious disease associated with immune deficiency
•- Febrile illness in the week before the LPS challenge.
•- Hypersensitivity to ticagrelor or any excipients
•- Active pathological bleeding
•- History of intracranial haemorrhage
•- history of dyspepsia
•- quantitative bleeding assessment tool (BAT) score > 3
•- Participation in another drug trial or donation of blood 3 months prior to the planned LPS

发起方

niversitair Medisch Centrum Sint Radboud